Skip to content

PTHS PTHS Commercial operations — Total Revenue

Other segment segments

Research and Development operations
$241K

Similar metrics at other companies

StoneX Group Inc. logo
SNEXCommercial — Total revenues
$44.73B+23.6%
Emergent Biosolutions logo
EBSCommercial Product sales — Total revenues
$42.9M-5.3%
Emergent Biosolutions logo
EBSCommercial Products — Total revenues
$42.9M-5.3%
Envela logo
ELACommercial — Revenue
$16.59M+44.4%
St. Joe Company logo
JOECommercial — Revenue
$17.42M-10.6%
Centene logo
CNCCommercial — Total revenues
$9.56B-5.8%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's commercial operations — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's commercial operations — total revenue?
PTHS (PTHS) reported commercial operations — total revenue of $10.67M in Q1 2026.
What does commercial operations — total revenue mean?
This metric represents the total gross income generated from the sale of goods or services within the company's commercial operations segment. It serves as a primary indicator of market adoption and the successful transition from clinical development to commercialization. Tracking this revenue stream helps investors evaluate the scalability and market demand for the company's therapeutic portfolio.